Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Mulitplicom's MID and MASTR Kits; Laboratoire Cerba's NIPT; More


Belgian company Multiplicom has launched a CE-IVD labeled MID kit for Illumina's MiSeq system as well as three germline mutation detection kits using the company's MASTR technology for maturity onset diabetes of the young, autosomal dominant hypercholesterolemia, and hypertrophic cardiomyopathy.

The MID kit is designed to be used with Multiplicom's MASTR assays, and each kit contains eight specific p7 MID Primers and six specific p5 MID Primers, enabling 48 possible p7-p5 MID combinations. It can be used for diagnostic purposes when combined with the CE-labeled MASTR Dx and MID Dx kits.

Laboratoire Cerba has launched its noninvasive prenatal test in France, Belgium, Luxembourg and parts of the Middle East and Africa. The test uses technology licensed from Sequenom to screen for fetal trisomies 21, 18, and 13.

Molecular diagnostic company Diagnovus has launched Engauge-cancer DLBCL Gene Panel, a next-gen sequencing-based panel for diffuse large B-cell lymphoma. The hotspot panel assesses 17 genes related to diffuse large B-cell lymphoma and has a turnaround time of seven to 10 days.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.